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Summary
SETTING: A 950 bed teaching hospital in Switzerland.
AIM: To describe the result of a contact investigation
among health care workers (HCW) and patients after ex-
posure to a physician with smear-positive pulmonary tuber-
culosis in a hospital setting using standard tuberculin skin
tests (TST) and Interferon-gamma release assay (IGRA).
METHOD: HCW with a negative or unknown TST at hir-
ing had a TST two weeks after the last contact with the in-
dex case (T0), repeated six weeks later if negative (T6). All
exposed HCW had a T-SPOT.TB at T0 and T6. Exposed
patients had a TST six weeks after the last contact, and a
T-SPOT.TB if the TST was positive.
RESULTS: Among 101 HCW, 17/73 (22%) had a positive
TST at T0. TST was repeated in 50 at T6 and converted
from negative to positive in eight (16%). Twelve HCW
had a positive T-SPOT.TB at T0 and ten converted from
negative to positive at T6. Seven HCW with a positive T-
SPOT.TB reverted to negative at T6 or at later controls,
most of them with test values close to the cut-off. Among
27 exposed patients tested at six weeks, ten had a positive
TST, five of them confirmed by a positive T-SPOT.TB.
CONCLUSIONS: HCW tested twice after exposure to a
case of smear-positive pulmonary TB demonstrated a pos-
sible conversion in 10% with T-SPOT and 16% with TST.
Some T-SPOT.TB reverted from positive to negative dur-
ing the follow-up, mostly tests with a value close to the cut-
off. Due to the variability of the test results, it seems advis-
able to repeat the test with values close to the cut-off before
diagnosing the presence of a tuberculous infection.
Key words: tuberculosis; outbreak management; latent
tuberculosis infection; contact investigations; IGRAs
Introduction
Patients with smear-positive pulmonary tuberculosis may
contaminate persons with whom they come in contact,
some of whom (about 10% according to the literature)
will progress to disease and transmit the infection further.
Screening exposed contacts for latent tuberculosis infection
(LTBI) and offering preventive treatment before the disease
develops is considered as one of the effective methods
for controlling tuberculosis, particularly in countries where
tuberculosis is a rare disease, and where resources and
equipment allow it [1–4]. As contacts of cases with con-
tagious pulmonary tuberculosis have a high risk of devel-
oping the disease in the near future, particularly if they
have immunological markers of infection [5], contact tra-
cing and preventive treatment of infected contacts is re-
commended whenever a case of smear-positive tuberculos-
is is detected [6].
A case of smear-positive tuberculosis was observed in a
health-care worker (HCW) at a large teaching hospital in
Switzerland. A contact tracing procedure was performed
among other HCW and patients in contact with the index
case. This paper describes the procedure using both tuber-
culin skin test (TST) and an Interferon Gamma Release As-
say (IGRA), the results and some open questions arising in
this setting.
Case report
A junior medical doctor from Cameroun arrived in
Switzerland in January 2005 and started working in the
University Hospital in Lausanne (CHUV). He was healthy
on arrival, but had prior contacts with patients with tuber-
culosis in his country of origin. Because of misunderstand-
ing, he did not undergo the pre-employment screening for
TB. By the 15th of April he noted the abrupt onset of pro-
ductive cough, weakness and malaise. He sought medical
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attention two weeks later, and was diagnosed with smear-
positive pulmonary tuberculosis. Cultures confirmed the
presence of a fully susceptible M. tuberculosis strain. Isol-
ation under negative pressure was ordered and a four drug
regimen with isoniazid, rifampicin, pyrazinamid and eth-
ambutol was started immediately. The patient was cured at
the end of therapy.
Method
As the onset of cough was abrupt beginning on the 15th of
April, the index case was considered as potentially infec-
tious during a period ranging from the 1st April and the be-
ginning of May when diagnosis was made and the index
case was isolated (one month period). All HCW working in
the same department as the index case during that period,
all workers in other departments with whom he was in con-
tact (operating theatre, emergency rooms) and all patients
treated by him during that period were identified and con-
tacted. All HCW exposed to the index case were asked to
fill out a questionnaire with demographic data, information
about prior BCG vaccination, prior exposure to tuberculos-
is and the self-estimated length of exposure to the index
case. Since the period of communicability extended over
a month and since most HCW had multiple contacts with
the index case during that time, the date of exposure for all
HCW was set at 15th of April as a proxy.
At that time the current policy for TB screening in HCW
in the hospital (at pre-employment and at regular intervals
for those in high risk settings or after occupational contact
with a patient with smear-positive TB) was to use TST. For
this investigation an IGRA (T-SPOT-TB®, Oxford Immu-
notec, Oxford, UK) was also used for the first time. Both
tests were performed according to the following protocol:
Protocol of investigation:
– HCW: prior TST (TST performed at pre-employment
health evaluation or at the last periodic control) was
used as baseline. HCW with no prior TST, or negative
prior TST or TST older than five years were retested
shortly after exposure (T0). Because T-SPOT.TB was
never used before in the routine contact-tracing in the
hospital and in order to obtain a baseline value it was
performed at T0 for all HCW in contact regardless of
the prior TST. The blood was drawn at the same day as
the application of the TST. Six weeks later (T6), a TST
was offered to all HCW with a negative TST at T0 and
a second T-SPOT.TB to all. T-SPOT.TB was re-
checked ten weeks later (T16) in 8 HCW in cases of
conversion.
– Patients: patients in contact with the index case were
contacted individually by a community nurse and were
informed about the investigation. According to the
usual procedure in Switzerland [7], they all had a TST
at T6. Contacts with a positive TST were tested at the
time of reading with T-SPOT.TB.
The TST was performed using the Mantoux method with
two units of RT23 tuberculin. A TST was considered pos-
itive if the induration was ≥10 mm. The T-SPOT.TB was
performed according to the manufacturer’s instruction. The
test was considered positive if the sample demonstrated the
presence of six spots more than the negative control. Con-
version was defined as a change from negative to positive,
reversion as a change from positive to negative, whatever
the values.
According to the current Swiss procedure [7], contacts with
a positive T-SPOT-TB test have to pass a medical examina-
tion and a chest X-ray. Those with a normal image are con-
sidered as possibly infected and offered a preventive treat-
ment with isoniazid for nine months or rifampicin for four
months. Contacts with an abnormal X-ray are assessed for
the possible presence of active tuberculosis. Contacts with
a positive TST not confirmed by T-SPOT.TB are informed
that they probably have not been contaminated and offered
clinical surveillance.
Statistical analysis
Descriptive statistics with absolute values and proportions
are presented. Odds ratios (OR) with the corresponding
95% confidence intervals (95%-CI) for TST and IGRA at
T0 and T6 depending on vaccination status and on prior ex-
posure to tuberculosis were calculated. To assess the binary
concordance among TST and IGRA at T0 and T6 kappa
statistics were presented [8]. All statistics were performed
using the Stata version 12.1 software (StataCorp. LP, Col-
lege Station, TX, USA)
Results
HCW
The total number of contacts to be investigated was 101.
The demographic data, distribution by professional cat-
egories, risk factors for prior exposure to TB, the estimated
time of exposure and the distribution of the test results
at initial and repeated screening are reported in table 1.
The majority (68%) of HCW had been vaccinated with
BCG (time elapsed since vaccination not known). Vaccin-
ated HCW had a higher rate of TST positivity at T0 com-
pared to non-vaccinated (29% vs 0% OR not calculable be-
cause there was nobody with prior BCG in one group) but
about the same rate of positivity of T-SPOT.TB at T0 (10%
and 11% respectively, OR 0.92 (95%-CI 0.17–4.90). Both
groups showed a comparable rate of conversion between
T0 and T6 with both TST and T-SPOT-TB (13% resp. 8%).
HCW with a known prior exposure to TB were more likely
to show a T-SPOT-TB positivity at T0 than non-exposed
although this was not statistically significant (20% vs 9%
respectively, OR 3.11 (95%-CI 079–12.27), whereas there
was no difference in the TST positivity at T0 (OR 0.82
with a 95%-CI 0.17–4.90). There was a very low inter-rate
agreement between TST and T-SPOT.TB both at T0 (.k =
0.09) and at T6 (.k = 0.13).
Conversion by both TST and T-SPOT.TB appear not to
correlate with the self-estimated duration of the exposure
to the index patient (table 1), although we were not able
to perform a multivariate logistical regression analysis due
to the low conversion rate both by TST and T-SPOT.TB
(table 1).
In the whole studied population, a possible conversion of
the TST (change from negative to positive) was observed,
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in 6/43 (14%) HCW from T0 to T6. T-SPOT.TB was pos-
itive at T0 in twelve and converted from negative at T0 to
positive at T6 in ten. Among the six HCW with a TST con-
version none were confirmed by T-SPOT.TB and among
ten T-SPOT converters, none demonstrated a TST conver-
sion (0% correlation). Furthermore T-SPOT-TB reverted
from positive at T0 to negative at T6 in two cases (table 2).
The T-SPOT.TB reverted to negative values in six patients
with prior conversion (T0–T6) 3 of them being in the “grey
zone” between six and nine spots and all with 15 spots or
less.
No HCW had a radiological abnormality or symptoms sug-
gestive of TB at control. As all HCW had a confirmed re-
cent exposure, we assumed that all contacts with a stable
or increasingly positive T-SPOT.TB test had an indication
for preventive chemotherapy. A preventive therapy was
offered but rejected by most of them.
Patients
Twenty-seven patients (all adults) were contacted and
tested by TST and T-SPOT six to eight weeks after the
last contact with the index case. Ten had a positive TST,
five of whom were confirmed by a positive T-SPOT.TB.
All patient with a negative TST and five with a positive
TST had a negative T-SPOT.TB. A preventive therapy was
offered to all patients with a positive T-SPOT.TB and ac-
cepted by four. One patient with a positive TST but negat-
ive T-SPOT.TB was also offered a preventive treatment.
Discussion
In a contact investigation performed among 101 HCW ex-
posed to a case of smear-positive tuberculosis in a hospital
and tested twice at six week intervals, we observed six TST
conversions and ten IGRA conversions between T0 and T6.
Globally, 21 HCW workers had at least one positive IGRA,
eight of whom reverted to negative values between T0 and
T6 or between T6 and T16. Thirty percent of them had
a possible previous exposure to TB. Two had received a
treatment for tuberculosis in the past but none had received
a preventive treatment.
Among 27 adult patients exposed to the same index case
and tested more than six weeks after the last contact, ten
had a positive TST, five of whom also had a positive IGRA.
No patient with a negative TST had a positive IGRA.
This contact investigation in a hospital setting among
HCW and patients posed several problems for the manage-
ment and interpretation of test results.
Choice of test procedure
As 68% of HCW had received a BCG vaccination in the
past and 30% had a possible prior exposure to tuberculosis,
the reliability of the TST as a tool for assessing the presen-
ce of infection was considered inappropriate, as a large pro-
portion of false positive results was expected, with a risk
of generating unnecessary anxiety, examinations and pre-
ventive treatment in uninfected contacts [9]. Therefore, all
contacts were offered a test with T-SPOT.TB, considered
Table 1: Study population and distribution of positive test results (TST and T-SPOT.TB) at initial screening and at control (by frequency of positivity related to number of
tests performed). The risk factors for TB infection prior to the current exposure were defined as: 1) birth in a country with a high prevalence of TB. 2) travel in such
countries for more than six months. 3) previous exposure to any person known to have TB. Immunodeficiency was defined as having HIV/AIDS, solid or bone marrow
transplantation or any other immunosuppressive drug (steroids, anti-TNF, etc). *OR and 95%-CI were calculated and the results are presented in the text.
Categories Total
(Nr)
Positive at T0 Conversion T0 to T6
by TST
(n = 73)
by T-SPOT.TB
(n = 100)
by TST By T-SPOT.TB
Age (mean/median in years) (35/38)
Gender
m
f
39
62
6/25 (24%)
11/48 (23%)
8/38 (21%)
4/62 (6%)
1/12 (8%)
5/31 (16%)
4/27 (15%)
6/55 (11%)
Age category
<35y
35–50y
50–65y
>65y
50 (50%)
34 (34%)
17 (17%)
0 (0%)
8 (16%)
6 (18%)
3 (18%)
0 (0%)
5 (10%)
3 (8.8%)
4 (3.5%)
0 (0%)
3 (6.0%)
2 (5.8%)
1 (5.8%)
0 (0%)
5 (10%)
5 (10%)
0 (0%)
0 (0%)
BCG vaccination
yes
no
unknown
68 (68%)
19 (19%)
14 (14%)
15/51 (29%)*
0/13 (0%)
2/10 (25%)
7/68 (10%)*
2/18 (11%)
3/14 (21%)
5/27 (18%)
1/9 (11%)
0/7 (0%)
8/59 (13%)
1/13 (8%)
0/10 (0%)
Prior exposure to TB
yes
no
unkonwn
30 (30%)
68 (68%)
3 (3%)
4/20 (20%)*
12/52 (23%)
1/1 (100%)
6/30 (20%)*
6/67 (9%)
0/3 (0%)
1/14 (7%)
5/29 (17%)
0/0 (0%)
4/23 (17%)
6/56 (11%)
0/3 (0%)
Time of exposure
<3h
3–8h
>8h
unknown
63 (63%)
26 (26%)
11 (11%)
1 (1%)
9/48 (18%)
5/15 (33%)
2/9 (22%)
1/1 (100%)
9/63 (14%)
2/26 (8%)
1/11 (9%)
0/0 (0%)
3/32 (9%)
3/8 (37%)
0/3 (0*)
0/0 (0%)
9/51 (17%)
1/22 (4%)
0/9 (0%)
0/0 (0%)
HCW categories
Physicians
Nurses
Others
19 (19%)
43 (43%)
39 (39%)
2/14 (14%)
9/31 (29%)
6/28 (21%)
2/19 (10%)
4/43 (9%)
6/38 (16%)
1/5 (20%)
3/20 (15%)
2/18 (11%)
0/14 (0%)
4/29 (14%)
6/29 (21%)
HCW with known immunodeficiency 0 (0%) 0 0 0 0
Total nr. HCW 101 17/73 (23%) 12/100 (12%) 6/43 (14%) 10/82 (12%)
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as more specific (no influence of prior BCG vaccination
and environmental mycobacteria) and potentially reducing
the need for further examination and preventive treatment
[10, 11]. It is generally assumed that IGRA have a higher
negative and positive predictive value for progression to
tuberculosis than TST, contacts with a positive IGRA result
having a significantly higher risk of progression to tuber-
culosis than contacts with a negative result [12, 13]. In our
study we found a very low inter-rate agreement between
TST and T-SPOT.TB both at T0 and at T6 possibly due to
the high rate of BCG vaccination in HCW. We also found
no correlation among conversion by TST and conversion
by T-SPOT.TB between T0 and T6. We are not able to ex-
plain these findings, which, translated in to clinical prac-
tice means that a contact screening performed only with
TST would have identified a different population to which
a preventive treatment potentially would have been offered.
Nonetheless in practice we considered that a conversion by
T-SPOT.TB was more relevant because we avoided false
TST results due to BCG vaccination.
Timing of the tests
Because of the high level of anxiety in the HCW and the
hospital management, the screening was organised rapidly
after the diagnosis of the index case and the first testing
was performed soon after the last possible contact (in av-
erage two weeks, defined as T0), in spite of the fact that
some tests results may have been positive as a consequence
of a prior infection. As the immune reaction after contact
establishes after several weeks, it was decided to repeat the
tests (TST in contacts with negative results and IGRA in
all) six weeks later, considering that this time would allow
for the development of an immune reaction in infected con-
tacts [14, 15]. The T-SPOT.TB tests which were positive at
T0 could have been the result of prior infection or the con-
sequence of the recent contact with the index case prior to
the diagnosis. The T-SPOT.TB tests which became posit-
ive between T0 and T6 were considered as a sign of recent
infection. Due to this uncertainty, all contacts with a pos-
itive test result at any time had a medical examination and
a chest X-ray before taking a decision of preventive treat-
ment or information and observation.
Degree of exposure and test results
It is generally admitted that close contacts of infectious pa-
tients have a higher risk of being infected than casual con-
tacts, the highest risk being in relatives sharing the same
habitation [5]. In this context, it may seem surprising that
there was apparently no correlation between the number of
hours of contact of the HCW with the index case (less than
three hours, three to eight and more than eight hours), but
this may reflect the fact that the contacts took place in well
ventilated hospital rooms and were not very close (work in
the same room without direct contact). On the other hand,
adults who were born in a country with a high prevalen-
ce of tuberculosis may have been infected during child-
hood and have a positive test result, as has been repeatedly
demonstrated among migrants [16]. In our study group,
persons with a prior exposure to TB (related to birthplace
or occupation) seem to have a higher frequency of positive
T-SPOT than those without exposure.
Conversions and reversions
The change from a negative to a positive test result (with
TST and with IGRA), defined as a conversion, is con-
sidered as a marker of a recent infection and an indication
for further examinations and proposal of a preventive treat-
ment. An intriguing phenomenon, which was frequently ig-
nored in the period where only the TST was available for
contact investigations, is the observation of a variation in
Table 2: Evolution of the number of spots between T0 and T6 among all HCW who had at least one positive test result with the current definition of cut-off (six and more
spots) and with a modified cut-off (16 spots and more). Contacts with positive IGRAs at T0 were considered as having a prior infection of unknown origin, contacts with a
change from negative to positive were considered as possible conversions, contacts with a change from positive (at T0 or T6) to negative (at T6 or T16) were interpreted
as reversion.
HCW nr. T0
n spots
T6
n spots
T16
n spots
Interpretation
Cut-off 6 spots
Interpretation
Cut-off 16 spots
1 47 68 infection infection
2 43 80 infection infection
3 34 3 reversion from positive reversion from positive
4 19 16 infection infection
5 16 20 infection infection
6 12 16 infection infection
7 12 7 infection negative
8 12 6 infection negative
9 10 8 infection negative
10 8 11 25 infection conversion
11 6 7 infection negative
12 6 0 reversion negative
13 2 8 2 reversion negative
14 2 7 conversion negative
15 1 12 12 conversion negative
16 1 11 5 reversion negative
17 1 6 conversion negative
18 0 15 0 reversion negative
19 0 12 0 reversion negative
20 0 10 conversion negative
21 0 9 0 reversion negative
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the level of positivity of the blood tests, some tests turning
from positive to negative if they are repeated. Changes in
level after a short time interval may be due to biological
variability [17, 18] or technical factors [19] or be the con-
sequence of a transient immunological stimulation in sub-
jects able to eliminate the mycobacteria soon after the con-
tact [20] or due to some other unknown factors. High rates
of both conversions and reversions are particularly notice-
able in serial testing context such as TB screening in HCW
[21–23]. Most of the changes in level or reversions are ob-
served for tests with values close to the cut-off defined by
the manufacturer. Therefore, some authors propose that the
cut-off be set at a higher level, for instance doubling the
level for positivity, particularly for repeated testing without
documented exposure to tuberculosis [24, 25]. Using 16
spots as a cut-off for positivity instead of six, 15 out of
21 tests results would have been considered as negative,
including seven of eight cases with an apparent reversion
and only one would be considered as a conversion. There
is currently no consensus about the optimal cut-off level
for serial testing and individual testing after contact, and
the elevation of the cut-off may have as a consequence
a decrease in sensitivity of the test [26, 27]. Reversal of
transiently positive tests may explain why the majority of
contacts with a positive test result never progress to tuber-
culosis. If only contacts with a strong and stable immuno-
logical reaction have a significant risk of developing tuber-
culosis, then the repetition of the tests, particularly in cases
with borderline results, may increase the efficiency of pre-
ventive treatment. In a study of contacts tested three times
over an observation period of 18 months, 54 among 134
untreated contacts reverted from positive to negative at
three months and 28/78 reverted to negative at 18 months
[28]. In spite of this, the exact definition of latent tubercu-
losis infection and the interpretation of positive immunolo-
gical tests remain somewhat elusive [29, 30].
Indication to preventive treatment
There is a general consensus that infected contacts of index
cases with smear-positive pulmonary tuberculosis have a
high risk of developing tuberculosis at a later date and
would therefore benefit from a preventive treatment [4, 31,
32]. The main obstacle to an efficient prevention is the low
rate of acceptance of preventive treatment by healthy con-
tacts, including health care workers [33–35]. Short treat-
ments, for instance four months of rifampicin instead of
nine months of isoniazid, are better accepted and have
a higher completion rate [36, 37]. Furthermore, a better
definition of infected contacts, for instance by selecting
for preventive treatment only the contacts with a stable or
strongly positive reaction, or with individual risk factors,
may improve the rate of adherence.
Limitations of the study
The study has several limitations. One of them is the fact
that the procedure for contact investigation was not the
same in all contacts (TST only for some of them) and that
most HCW had two T-SPOT.TB and only some of them
had three tests. Therefore, the role of prior exposure to TB
before the current outbreak and the exact number of rever-
sions of positive tests cannot be assessed.
Another major limitation of our study is the fact that the
time of exposure to the index case was unknown for most
HCW and had to be set arbitrarily. We cannot exclude that
some HCW were exposed earlier than indicated and that
the TST and T-SPOT.TB-test performed at T0 were actu-
ally performed four to six weeks after exposure.
As we used T-SPOT.TB for the first time in our institution
within the context of a contact investigation, we did not
consider the possibility of reversion and false positivity and
did not repeat the positive or borderline tests, as would be
the case now. Therefore we were not able to assess the as-
say variability.
Conclusions
1. Contact tracing among HCW and patients exposed to
a staff member with pulmonary tuberculosis is
difficult, as many adults have been vaccinated with
BCG or have already been exposed to tuberculosis in
the past and may have a remote infection. Tuberculin
skin test is considered unreliable in this setting.
IGRAs are more specific but their interpretation is
still subject to controversy.
2. In our setting and using the current definition of
positivity, T-SPOT.TB demonstrated 22% of latent
infection, 10% probably recent (T-SPOT.TB
conversions). Among exposed patients, the rate of
possible infection was 19%.
3. Contacts tested several times with T-SPOT
demonstrate a reversion in seven of 21 cases. This
may be due to variations of the test value close to the
cut-off or to a spontaneous elimination of the
mycobacteria by the organism. Re-testing the
contacts with a weakly positive test result and setting
a higher cut-off for the definition of conversion may
increase the efficiency of the procedure.
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